Our mission is to transform the lives of patients worldwide with revolutionary anti- inflammatory therapeutics.
Serpin Pharma is creating a new class of medicines using a key, short peptide fragments derived from natural molecules from the SERPINs (Serine Protease Inhibitors) family to treat patients suffering autoimmune and inflammatory diseases.
Serpin Pharma has developed a synthetic peptide, SP16, derived from a naturally occurring serine protease inhibitor (SERPIN) containing a unique anti-inflammatory core motif that targets a key immune regulating receptor, LRP1 (Low-density lipoprotein receptor–related protein-1). The anti-inflammatory and immunomodulatory effects of the peptide have been demonstrated in a variety of auto-immune and acute inflammatory diseases and prominently used in the lead indication acute myocardial infarction (AMI), where treatment with SP16 protects cardiac tissue, reduces infarct size and restores heart function. SP16 is approved by the FDA to proceed to human clinical trials for AMI.
Additional planned development programs include Traumatic Brain Injury (TBI), Ischemic Stroke, and Graft Versus Host Disease (GVHD).
Location: Manassas, VA
Our Name: SERPIN Pharma was chosen to acknowledge the origin and basis for our proprietary drugs- SERPINs
CEO: Guy Yachin, Eng. MBA
Lead Program: Initial Investigational New Drug Application (IND) 127746
Serpin Peptide: SP16 – Use of SP16 as Adjunctive Treatment to Reduce Acute Myocardial Infarct Size in Patients with ST-Segment Elevation Acute Myocardial Infarction (STEMI).
Serpin Pharma is a privately held biotech company with research facilities in Northern Virginia, USA.